Announced Action for October 4, 2002
Date
Following a public comment period, the Commission has approved the issuance of a modified final consent order in the matter concerning Biovail Corporation (Biovail) and its branded drug Tiazac...
Displaying 1301 - 1320 of 1557
Sep09
Workshop on Health Care and Competition Law and Policy
-
The FTC held a public workshop on the implications of competition law and policy for health care financing and delivery. The workshop considered the impact of competition law and policy on the cost...
Announced Action for September 6, 2002
Date
Following a public comment period, the Commission has approved a final consent order, without modifications, and a letter to the commenter of record in the matter concerning Immunex Corporation and...
Amgen Inc. and Immunex Corporation
Amgen settled antitrust charges that its proposed $16 billion acquisition of Immunex Corporation would reduce competition and tend to create a monopoly in the biopharmaceutical markets for neutrophil (white blood cell) regeneration factors; tumor necrosis factor (TNF) inhibitors; and interleukin-1 (IL-1) inhibitors. The consent order requires the firms to sell all of Immunex's assets related to Leukine -a neutrophil regeneration factor -to Schering AG; license certain intellectual property rights to TNF inhibitors to Serono S.A.; and license certain intellectual property rights related to IL-1 inhibitors to Regeneron Pharmaceuticals Inc.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0210059
Docket Number
C-4056
Federal Trade Commission Announces Formation of Merger Litigation Task Force
Date
Joe Simons, Director of the Federal Trade Commission's Bureau of Competition, today announced the formation of the Merger Litigation Task Force, which will be headed by Michael Cowie, an Assistant...
Denver-Area Physician Practice Groups and Their Agent Agree to Settle FTC Charges of Fixing Fees
Date
Eight Denver, Colorado, area physician practice groups specializing in obstetrics and gynecology (OB/GYNs), along with their non-physician agent and his corporation, have agreed to settle Federal...
Dallas-Fort Worth-area Physicians Group Agrees to Settle
Date
System Health Providers (SHP) and its parent corporation, Genesis Physicians Group, Inc. (GPG), most of whose approximately 1,250 members are physicians practicing in the eastern part of the Dallas...
Announced Actions for August 20, 2002
Date
The Commission has approved the issuance of a final consent order in the matter concerning Biovail Corporation and Elan Corporation, plc, and authorized a response letter to be sent to the one...
Physician Integrated Services of Denver, Inc., Michael J. Guese, M.D., and Marcia L. Brauchler
A consent order settled charges that a Denver, Colorado physician organization and its members, its president, Dr. M. J. Guese, and its non-physician consultant, M. A. Brauchler, increased fees for services through collective boycotts and agreements in a effort to fix the prices they would receive from health care insurance payers. The order prohibits the organization and its members and other respondents from entering into any agreement with insurance payers or providers to negotiate on behalf of the physicians group.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0110173
Aurora Associated Primary Care Physicians, L.L.C., Richard A. Patt, M.D., Gary L. Gaede, M.D., and Marcia L. Brauchler
A consent order settled charges that the organization of internists, pediatricians, family physicians and general practitioners in the Aurora, Colorado area engaged in boycotts and entered into collective negotiations with health care insurers in an effort to increase the costs of physician services. The order prohibits the organization from entering into any agreement with insurance payers or providers to negotiate fees on behalf of the physicians group.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0110174
Resolving Anticompetitive Concerns, FTC Clears $16 Billion Acquisition of Immunex Corp. By Amgen Inc.
Date
Under the terms of a proposed consent agreement announced today, the Federal Trade Commission would allow Amgen Inc.'s (Amgen) proposed $16 billion acquisition of Immunex Corporation (Immunex) to...
Administrative Law Judge Dismisses FTC Allegations of Anticompetitive Conduct by Schering-plough and Upsher-Smith
Date
In an initial decision filed on June 27, 2002 and announced today, Administrative Law Judge (ALJ) D. Michael Chappell dismissed all allegations of anticompetitive conduct in a March 2001 Federal Trade...
Report
Generic Drug Entry Prior to Patent Expiration: An FTC Study
Date
File
Text of the Report
(3.01 MB)
Biovail Corporation
The Commission charged Biovail Corporation with illegally acquiring an exclusive patent license for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further alleged that Biovail, in an effort to maintain its monopoly, wrongfully listed the acquired license in the U.S. Food and Drug Administration’s “Orange Book” for the purpose of blocking generic competition to its branded Tiazac. The consent order requires Biovail to divest part of its exclusive rights to DOV; prohibits the firm from taking any action that would trigger additional statutory stays on final FDA approval of a generic form of Tiazac; and also prohibits Biovail from wrongfully listing any patents in the Orange Book for a product for which the company already has an New Drug Application from the FDA.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
011 0094
Docket Number
C-4060
Announced Action for June 4, 2002
Date
Administrative Law Judge D. Michael Chappell has issued an order extending until June 26, 2002, the deadline for filing the initial decision in the matter of Schering-Plough Corporation (Schering)...
Obstetrics and Gynecology Medical Corporation of Napa Valley, a corporation et al.
A doctors’ group consisting of nearly every obstetrician and gynecologist with active medical staff privileges at the two general acute care hospitals in Napa County, California settled charges that they restrained price and other competition by engaging in illegal agreements to fix fees and other terms of dealing with health care insurance plans. According to the complaint issued with the consent order, the doctors refused to deal with the third party payers except on collectively determined terms. The consent order not only prevents the doctors from engaging in similar practices in the future but also requires the dissolution of the group.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0110153
Two Denver-area Physician Groups Agree To Settle FTC Charges of Fixing Fees
Date
Two Denver, Colorado-area physician organizations, Physician Integrated Services of Denver, Inc. (PISD), and Aurora Associated Primary Care Physicians, L.L.C. (AAPCP), along with their respective...
Prepared Statement of the Federal Trade Commission On Pharmaceutical Industry
Date
By
Timothy J. Muris, Former Chairman
File
Testimony
(183.84 KB)
Wrongful "Orange Book" Listing Raises Red Flag with FTC; Leads to Consent Order with Biovail Corp. Concerning its Drug Tiazac
Date
The Federal Trade Commission today announced its first complaint against - and consent order with - a pharmaceutical manufacturer for allegedly illegally acquiring an exclusive patent license and...
Public Statement
The Antitrust Implications of "Clinical Integration:" An Analysis of FTC Staff's Advisory Opinion to MedSouth
Date
This article is based on a speech delivered at the Saint Louis University Health Law Symposium on April 12, 2002, and is published in issue 47:2 of the Saint Louis University Law Journal, at page 217.
Displaying 1301 - 1320 of 1557